Physician profile
Randall Keith Hildebrand
NPI 1770547416
$20,646.28
in general payments reported to CMS, 2019-2025
9 companies · $3,353 in 2025
The $3,353 reported for 2025 was more than what 78% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,051 · 2020: $1,680 · 2021: $6,936 · 2022: $3,023 · 2023: $21.90 · 2024: $2,581 · 2025: $3,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,706 · Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,706.37 |
| Food and Beverage | $2,249.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $13,074.95 | 2019-2025 | Persona, Comprehensive Shoulder System |
| Arthrex, INC. | $5,611.02 | 2019-2021 | |
| Titan Surgical Group, LLC | $1,789.76 | 2019-2021 | |
| Stryker Corporation | $60.89 | 2019 | |
| Bioventus LLC | $31.06 | 2025 | Durolane |
| Organogenesis INC. | $24.78 | 2021 | |
| Heron Therapeutics, INC. | $21.90 | 2023 | Zynrelef |
| Ferring Pharmaceuticals INC. | $16.51 | 2024 | Euflexxa |
| Linvatec Corporation | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Hildebrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.